[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339894-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339894-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","treatment-patterns-in-advancedmetastatic-non-small-cell-lung-cancer-in-china-results-from-the-cancermpact-survey-2021","Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact survey 2021","","Report presents treatment patterns for advanced/metastatic non-small-cell lung cancer (NSCLC) in China based on a physician survey. A total of 206 Chinese physicians from 27 urban mainland cities shared their September 2021 practices. Findings show distinct first-line use by histology and PD-L1 status, with checkpoint inhibitors applied in over half of PD-L1-positive cases. Treatment choices also differed for driver-mutated NSCLC, often favoring targeted therapy or platinum-based combinations. Authors conclude that decisions vary by histology, PD-L1, and driver mutations, reflecting growing complexity in China as treatment options expand.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/treatment-patterns-in-advancedmetastatic-non-small-cell-lung-cancer-in-china-results-from-the-cancermpact-survey-2021/339894/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/treatment-patterns-in-advancedmetastatic-non-small-cell-lung-cancer-in-china-results-from-the-cancermpact-survey-2021/339894.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-21","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the aim of the CancerMPact 2021 physician survey?","Question",{"text":63,"@type":64},"To describe treatment patterns for advanced/metastatic non-small-cell lung cancer in China based on physician-reported practice.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many physicians and cities participated, and when was the survey conducted?",{"text":68,"@type":64},"A total of 206 physicians from 27 urban mainland cities participated, with the survey conducted in September 2021.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors most influenced treatment choices in the results?",{"text":72,"@type":64},"Treatment choices varied by histology, PD-L1 status, and driver mutations, including how biomarker testing informed drug selection.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339894,1790922289,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Research Article  \nTreatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact 􀀂R survey 2021  \nLaura Durbin*,1, Bhavna Murali1, Song Li1, Stephanie Hawthorne1 & Otvio Clark1 1 Oracle Life Sciences, Austin, TX 78741, USA  \n*Author for correspondence: [laura.durbin@cernerenviza.com](laura.durbin@cernerenviza.com)  \nAim: To report the treatment patterns of advanced/metastatic non-small-cell lung cancer (NSCLC) in China from a physician survey (CancerMPact􀀂R ) . Materials & methods: A total of 206 Chinese physicians from 27 cities in urban mainland China reported on their treatment of NSCLC in September 2021 . Results: Platinum doublets received 70 . 5% utilization for squamous NSCLC with PD-L1 expression \u003C1% in first-line, whereas nonsquamous NSCLC was treated with platinum doublets (35.2%) or bevacizumab with platinum doublets (35 .3%) . Checkpoint inhibitors were utilized in >50% of all PD-L1-positive NSCLC cases. Driver-mutated NSCLC was most frequently treated with targeted therapy or platinum-based combinations. Conclusion: NSCLC treatment in China varies by histology, PD-L1 status and driver mutations, illustrating the complexity of decision-making for Chinese physicians as treatment markets expand.  \nPlain language summary: The most common type of lung cancer is called non-small-cell lung cancer (NSCLC) . When lung cancer spreads beyond the lung, it is called advanced. Doctors in China who treat advanced NSCLC were identified. They were surveyed in September 2021 and asked about how they treat their patients. The survey included 206 doctors from 27 cities in China. There are many drugs available for NSCLC. This means that it can be hard for doctors to decide how to treat their patients. The doctors in China often reported using multiple drugs together, instead of using only one drug. One type of drug that can be used to treat NSCLC is called a checkpoint inhibitor (CPI) . The doctors reported that they often used CPIs to treat their patients. They also reported that they were more likely to use CPIs made in China rather than CPIs that were made outside of China. Before receiving treatment, most patients were tested for biomarkers. Biomarkers can tell doctors important information about cancers. Doctors can use biomarkers to help decide which treatments to offer their patients. In China, the doctors often did use certain drugs based on patient biomarkers. This choice often depended on the specific biomarker that the patient had. There are many different factors for doctors to consider when treating NSCLC. More and more drugs are becoming available to use in China. While this is good news for patients with cancer, treatment decisions are becoming more complex for doctors.  \nFirst draft submitted: 25 May 2023; Accepted for publication: 20 March 2024; Published online:  \n2 May 2024  \nKeywords: biomarkers • chemotherapy • immunotherapy • lung  \nLung cancer is the most common form of cancer in China, with approximately 900,000 new cases diagnosed each year [1] . It is also the deadliest cancer in this country, with approximately 24% of all cancer deaths in China attributed to lung cancer [2] . Whereas in the USA the incidence and mortality rates of lung cancer have been declining along with a decrease in smoking prevalence and an increase in clean air legislative measures, China has observed a gradual increase in lung cancer incidence and mortality rates as smoking prevalence rates also continue to increase and as approximately 70% of urban areas are exposed to air quality that has reached a hazardous level [3,4] . Non-small-cell lung cancer (NSCLC) is the most common histological subtype of lung cancer, accounting for approximately 85% of all lung cancer cases [5] . Treatments currently available for NSCLC are considered noncurative, with the singular exception of complete surgical resection for patients with early-stage disease [5– 8] . In the advanced/metastatic setting, system","cbCainSScMF0zsxd","https://ap.wps.com/l/cbCainSScMF0zsxd","pdf",1997268,13,"English","# Aim and rationale\n## Survey materials and methods\n# Results by histology, PD-L1, and biomarkers\n## Treatment patterns and utilization\n# Conclusion and implications\n## Complexity of treatment decision-making","[{\"question\":\"What was the aim of the CancerMPact 2021 physician survey?\",\"answer\":\"To describe treatment patterns for advanced/metastatic non-small-cell lung cancer in China based on physician-reported practice.\"},{\"question\":\"How many physicians and cities participated, and when was the survey conducted?\",\"answer\":\"A total of 206 physicians from 27 urban mainland cities participated, with the survey conducted in September 2021.\"},{\"question\":\"Which factors most influenced treatment choices in the results?\",\"answer\":\"Treatment choices varied by histology, PD-L1 status, and driver mutations, including how biomarker testing informed drug selection.\"}]","Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact survey 2021 | PDF",1790032975,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/308f62db1a0017e9c44960b8f0305949.webp",983,1322,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5a1be7129525108122cc592e174332a.webp",982,1321,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9764f043e9687f2f8fca7604e95b207.webp",981,1319,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/569727d98342b06499bf43d6982987b1.webp",980,1318]